DGAP-News: Heidelberg Pharma AG
/ Key word(s): Conference
10.09.2020 / 07:56
The issuer is solely responsible for the content of this announcement.
Heidelberg Pharma Announces Participation at Various Conferences
Ladenburg, Germany, 10 September 2020 – Heidelberg Pharma AG (FSE: HPHA) today announced that they will participate at the following events. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology, and to advance the biological mode of action of the toxin as a novel therapeutic principle.
H.C. Wainwright 22nd Annual Global Investment Conference (virtual format)
Details of the presentation
International HealthTech Innovation Days (mixed format)
Dr. Jan Schmidt-Brand will participate as a speaker on 5th October 2020 at 05:30 pm in the podium discussion “Opportunities and challenges for Innovative Healthtech companies in Europe”.
About Heidelberg Pharma’s proprietary ATAC technology
About Heidelberg Pharma
Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com.
This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.
10.09.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||Heidelberg Pharma AG|
|Phone:||+49 (0)89 41 31 38 – 0|
|Fax:||+49 (0)89 41 31 38 – 99|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1129635|
|End of News||DGAP News Service|